The Candidate Antigens to Achieving an Effective Vaccine Against Staphylococcus Aureus Publisher



Jahantigh HR^{1, 2} ; Faezi S³ ; Habibi M⁴ ; Mahdavi M⁵ ; Stufano A^{1, 2} ; Lovreglio P² ; Ahmadi K⁶ Show Affiliations
Source: Vaccines Published:2022

Abstract

Staphylococcus aureus (S. aureus) is an opportunistic pathogen that causes various inflamma-tory local infections, from those of the skin to postinfectious glomerulonephritis. These infections could result in serious threats, putting the life of the patient in danger. Antibiotic-resistant S. aureus could lead to dramatic increases in human mortality. Antibiotic resistance would explicate the failure of current antibiotic therapies. So, it is obvious that an effective vaccine against S. aureus infections would significantly reduce costs related to care in hospitals. Bacterial vaccines have important impacts on morbidity and mortality caused by several common pathogens, however, a prophylactic vaccine against staphylococci has not yet been produced. During the last decades, the efforts to develop an S. aureus vaccine have faced two major failures in clinical trials. New strategies for vaccine development against S. aureus has supported the use of multiple antigens, the inclusion of adjuvants, and the focus on various virulence mechanisms. We aimed to present a compressive review of different antigens of S. aureus and also to introduce vaccine candidates undergoing clinical trials, from which can help us to choose a suitable and effective candidate for vaccine development against S. aureus. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.